• Twitter
  • LinkedIn
  • Facebook
ARK Investment Management
  • Solutions
    • Institutional Accounts
    • Separately Managed Accounts
    • Mutual Fund
    • Exchange-Traded Funds
  • Advisor Services
    • Strategies
    • Our Clients
  • Research
    • Blogs
    • Podcast
    • White Papers
    • Webinars
    • Newsletter
    • ARK Big Ideas 2019
  • About ARK
    • Philosophy
    • Investment Process
    • Team
    • In The News
  • Contact
  • Search
  • Menu
You are here: Home / Research / Oncology
  • ark-disrupt-banner-143

    ARK Disrupt Issue 143: SpaceX, Autonomous, ITS World Congress, Cancer Detection, Meituan, Bitmain, & Paige.AI

    September 24, 2018 | by ARK Invest | News
    Mentioned Companies: ALL, BRK.A, FB, GOOGL, GRPN, NVDA, PGR, STFGX

    Please enjoy ARK Disrupt Issue 143. This blog series is based on ARK Brainstorming, a weekly discussion between our CEO, Director of Research, thematic analysts, ARK’s theme developers, thought leaders, and investors. It is designed to present you with the most recent innovation takeaways and to keep you engaged in an ongoing discussion on investing in […]

  • Cepheid, ark research, cancer detection, innovation

    Cancer Detection Could be Faster and Cheaper with Cepheid’s New Test

    May 08, 2015 | by James Bannon, ARK Analyst | Health
    Mentioned Companies: ABT, CPHD, FMI, GHDX, MYGN

    Today, the detection of cancer is time consuming and expensive. Tissue samples from molecular diagnostic tests must be mailed to a lab and sequenced or otherwise analyzed. In the United States, the process can take between seven and fourteen days, and costs $4,000 to $8,000. Test results from Foundation Medicine , Myriad Genetics , and […]

  • immunosignature, immunosignaturing, cancer, genome, genomics, ark, ark investment management, investment managment, investing, new york, etfs, ARKG, arkgenome, genomic revolution

    Immunosignatures Detect Cancer at Very Early Stages

    September 16, 2014 | by James Bannon, ARK Analyst | Health
    Mentioned Companies: CLVS, FMI, GE, PHG, SIE, VCYT

    A new blood test, called immunosignaturing 1, has the potential to change the cancer-care landscape dramatically. Now in research labs, it promises to detect breast cancer as early as a year before traditional diagnosis, with 90% certainty. Early diagnosis is an important factor in predicting cancer survival rates. Patients diagnosed with Stage I breast cancer […]

Subscribe to ARK Research

ARK’s Podcast On

ark podcast, fyi podast, for your innovation podcast, ark invest podcast, innovation podcast, investment podcast     ark podcast, fyi podast, for your innovation podcast, ark invest podcast, innovation podcast, investment podcast     ark podcast, ark disruptive innovation, fyi podcast, ark podcast     Image result for stitcher badge

New Call-to-action
 ARK Original Research

All original research is vetted through ARK’s research ecosystem and by its Director of Research. Every published article is reviewed by ARK’s CEO/CIO Catherine D. Wood.

Follow ARK on Twitter

Tweets by @ARKinvest

ADVISOR SERVICES

Strategies
Solutions
Thought Leadership
Our Clients

EXPLORE ARK ETFs

RESEARCH

Blogs
Podcast
White Papers
Webinars
Newsletter
Big Ideas 2019

ABOUT ARK

ARK Philosophy
ARK Process
ARK Team
Theme Developers
Board of Directors

CONTACT

FAQs
Press and Media
Job Opportunities

©2019, ARK Investment Management LLC (“ARK”). All content is original and has been researched and produced by ARK unless otherwise stated. No part of ARK’s original content may be reproduced in any form, or referred to in any other publication, without the express written permission of ARK. The content is available for informational purposes only and is subject to change without notice. All statements made regarding companies or securities or other financial information on this site or any sites relating to ARK are strictly beliefs and points of view held by ARK or the third party making such statement and are not endorsements by ARK of any company or security or recommendations by ARK to buy, sell or hold any security. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, please see the Terms of Use for this site.
  • Privacy Policy
  • Terms of Use
  • PATENT
Scroll to top